Perelman School of Medicine at the University of Pennsylvania

Brady Lab

Header Image

PUBLICATIONS

PEER REVIEWED RESEARCH PUBLICATIONS (*shared first author or #shared corresponding author): 

  1. Bond, S.E., Beratan, N.R., Bond, M.K., Brady, D.C., & Jordan-Sciutto, K.L. Copper as a novel regulator of PERK. bioRxiv (2022). 
  2. Williams, P.A., Parham, L.R., Acheampong, K.K., Danan, C.H.m Ma, X., Simon, L.A., Naughton, K.E., Karakasheva,   T., Whelan, K.A., Brady, D.C., Shaffer, S.M., & Hamilton, K.E. IGF2BP1/IMP1 contributes to autophagy modulation directly via MAP1LC3B. bioRxiv(2022).
  3. Pezacki, A.T.*, Matier, C.D.*, Gu, X., Kummelstedt, E., Bond, S.E., Torrente, L., Jordan-Sciutto, K.L., DeNicola, G.M., Su, T.A.#Brady, D.C.#, & Chang, C.J.# Oxidation state-specific fluorescent copper sensors reveal oncogene-driven redox changes that regulate labile copper(II) pools. Proc. Natl. Acad. Sci. U. S. A. 119, e2202736119 (2022).
  4. Tsang, T. *, Gu, X.*, Posimo, J.M., Davis, C.I., Miller, Z., & Brady, D.C. BRAFV600E-driven lung adenocarcinoma requires copper to sustain autophagic signaling and processing. Mol Cancer Res. 20, 1096-1107 (2022).
  5. Chojnowski J.E., Li R., Tsang T., Alfaran F.H., Dick A., Cocklin S., Brady D.C., Strochlic T.I. Copper Modulates the Activity of Protein Kinase CK2. Front Mol Biosci. 9, 9:878652 (2022).
  6. Doan, M.T., Neinast, M.D., Varner, E.L., Bedi, K., Bartee, D., Jiang, H., Trefely, S., Xu, P., Singh, J.P., Jang, C., Rame, E., Brady, D.C., Meier, J.L., Marguiles, K., Arany, Z., & Snyder, N.W. Direct anabolic metabolism of three-carbon propionate to a six-carbon metabolite occurs in vivo across tissues and species. J Lipid Res 63, 100224 (2022).
  7. Chaves-Moreira, D., Mitchell, M.A., Reddy, J., Brady, D.C., Sidoli, S., Garcia, B.A., Morin, P.J., Lawrenson, K., & Drapkin, R. PAX8 drives ovarian cancer angiogenesis through interaction with SOX17. Sci Signal 15, eabm2496 (2022).
  8. Roby, K.C., Lieberman, A., Kim, B., Rodriguez, N., Posimo, J.M., Tsang, T., Vergindas, I.I., Pure, E., Brady, D.C., Koumenis, C., & Ryeom, S.W. Loss of p19Arf Promotes Fibroblast Survival During Leucine Deprivation. Biol Open 11, bio058728 (2022).
  9. Grasso, M., Bond, G.J.*, Kim, Y.J.*, Boyd, S., Dzebo, M.M., Valenzuela, S., Tsang, T., Schibrowsky, N.A., Alwan, K.B., Blackburn, N.J., Burslem, G.M., Wittung-Stafshede, P., Winkler, D.D., Marmorstein, R., & Brady, D.C. The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation. J Biol Chem 297, 101314 (2021).
  10. Davis, C.I., Gu, X., Kiefer, R. M., Ralle, M., Gade, T.P., & Brady D.C. Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. Metallomics 12, 1995-2008 (2020).
  11. Blockhuys, S., Brady D.C., & Wittung-Stafshede, P. Evaluation of copper chaperone ATOX1 as prognostic biomarker in breast cancer. Breast Cancer 27, 505-509 (2020).
  12. Tsang, T.*, Posimo, J.M.*, Guidiel, A.A., Cicchini, M., Feldser, D.M., & Brady D.C. Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell Biol 22, 412-424 (2020).
  13. Kim, Y.J., Tsang, T., Posimo, J.M, Anderson, G.R., & Brady, D.C. Inhibition of BCL2 family members increases the efficacy of copper chelation in BRAFV600E-driven melanoma. Cancer Res 801387-1400 (2020).
  14. Rasool, R.U.*, Natesan, R.*, Deng, Q.*, Aras, S., Lal, P., Effron, S.S., Mitchell-Velasquez, E., Posimo, J.M., Carskadon, S., Baca, S.C., Pomerantz, M.M., Siddiqui, J., Schwartz, L.E., Lee, D.J., Palanisamy, N., Narla, G., Den, R.B., Freedman, M.L., Brady, D.C., & Asangani, I.A. CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation. Cancer Discov 9, 1538-1555 (2019).
  15. Chung, C.Y.*, Posimo, J.M.*, Lee, S.*, Tsang, T.*, Davis, J.M., Brady, D.C.#, & Chang, C.J.# Activity-based ratiometric FRET probe reveals oncogene-driven changes in labile copper pools induced by altered glutathione metabolism. Proc. Natl. Acad. Sci. U. S. A. 116, 18285-18294 (2019).
  16. Kim, Y.J., Bond, G.J., Tsang, T., Posimo, J.M, Busino, L., & Brady, D.C. Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma. Metallomics 11, 1430-1440 (2019).
  17. Katona, B.W., Glynn, R.A., Paulosky, K.E., Feng, Z., Davis, C.I., Ma, J., Berry, C.T., Szigety, K.M., Matkar, S., Liu, Y., Wang, H., Wu, Y., He, X., Freedman, B.D., Brady, D.C., & Hua, X. Combined menin and EGFR inhibitors synergize to suppress colorectal cancer via EGFR-independent and calcium-mediated repression of SKP2 transcription. Cancer Res 79, 2195-2207 (2019).
  18. Rivera-Reyes, A.*, Ye S.*, Marino,G., Egolf, S., Ciotti G., Chor S., Liu Y., Posimo, J.M., Park, P.M., Pak, K., Sostre-Colon, J., Tameire, F., Leli, N.M., Koumenis, C., Brady, D.C., Mancuso, A., Weber, K., Gladdy, R., Qi, J., & Eisinger-Mathason, T.S.K. The YAP1-NF-kB axis promotes sarcomagenesis by inactivating circadian clock-mediated unfolded protein responses and autophagy. Cell Death Dis 9, 1108 (2018).
  19. Sadeghi R.S., Kulej, K., Kathayat, R.S., Garcia, B.A., Dickinson, B.C., Brady, D.C.#, & Witze, E.S.# Wnt5a Signaling Induced Phosphorylation Increases Acyl Protein Thioesterase 1 Activity and Promotes Melanoma Metastatic Behavior.  Elife 7, pii: e34362  (2018). 
  20. Brady, D.C.*#, Crowe, M. S.*, Greenberg, D.N. & Counter, C.M.# Copper chelation inhibits BRAFV600E-driven melanomagenesis and counters resistance to BRAFV600E and MEK1/2 inhibitors. Cancer Res 77, 6240-6252 (2017).   
  21. Rebecca, V.W.*, Nicastri, M.C.*, McLaughlin, N., Fennelly, C., Mcafee, Q.W., Ronghe, A., Nofal, M., Lim, C.Y., Witze, E.S., Chude, C.I., Zhang, G., Alicea, G.M., Piao, S., Murugan, S., Ojha, R., Levi, S., Wei, Z., Barber-Rotenberg, J., Murphy, M.E., Dr. Mills, G.B., Lu, Y., Rabinowitz, J.D., Marmorstein, R., Liu, Q., Liu, S., Xu, X., Herlyn, M., Zoncu, R., Brady, D.C., Speicher, D.W., Winkler, J.D.#, & Amaravadi, R.K.# A unified approach to targeting the lysosome's degradative and growth signaling roles. Cancer Discov 7,1266-1283 (2017)
  22. Sammons, S., Brady, D.C., Vahdat, L.T., & Salama, A.K.S. Copper suppression as a cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma. Melanoma Manag 3, 207-216, (2016).  
  23. Chen, H.Y., Brady, D.C., & Villanueva, J. Double Trouble: Kinase domain duplication as a new path to drug resistance. Pigment Cell Melanoma Res 29, 493-495 (2016).
  24. Brady, D. C., Crowe, M. S., Turski, M. L., Hobbs, G. A., Yao, X., Chaikuad, A., Knapp, S., Xiao, K., Campbell, S. L., Thiele, D. J. & Counter, C. M. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 509, 492-496 (2014).
  25. Turski, M. L.*, Brady, D. C.*, Kim, H. J., Kim, B. E., Nose, Y., Counter, C. M., Winge, D. R. & Thiele, D. J. A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol 32, 1284-1295 (2012).
  26. Kashatus, D. F., Lim, K. H., Brady, D. C., Pershing, N. L., Cox, A. D. & Counter, C. M. RALA and RALBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol 13, 1108-1115 (2011).
  27. Zipfel, P. A., Brady, D. C., Kashatus, D. F., Ancrile, B. D., Tyler, D. S.#& Counter, C. M.Ral activation promotes melanomagenesis. Oncogene 29, 4859-4864 (2010).
  28. Lim, K. H.*, Brady, D. C.*, Kashatus, D. F., Ancrile, B. B., Der, C. J., Cox, A. D.#, & Counter, C. M.Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol 30, 508-523 (2010).
  29. O'Hayer, K. M., Brady, D. C., & Counter, C. M. ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis 30, 1841-1847 (2009).
  30. Madigan, J. P., Bodemann, B. O., Brady, D. C., Dewar, B. J., Keller, P. J., Leitges, M., Philips, M. R., Ridley, A. J., Der, C. J., & Cox, A. D. Regulation of Rnd3 localization and function by protein kinase C alpha-mediated phosphorylation. Biochem J 424, 153-161 (2009).
  31. Brady, D. C., Alan, J. K., Madigan, J. P., Fanning, A. S., & Cox, A. D. The transforming Rho family GTPase Wrch-1 disrupts epithelial cell tight junctions and epithelial morphogenesis. Mol Cell Biol 29, 1035-1049 (2009).

PEER REVIEWED COMMENTARIES, EDITORIALS, PERSPECTIVIES, & REVIEWS (* shared first authorship or # shared corresponding author):

  1. Carr, R.M.*, Lane-Fall, M.B.*, South, E., Brady D.C., Momplaisir, F., Guerra, C.E., Montoya-Williams, D., Dalembert, G., Lavizzo-Mourey, R., & Hamilton, R. Academic careers may be casualties of the COVID-19 pandemic for many minority researchers: Strategies to Stem the Tide. Sci Transl Med 13, eabe7189 (2021).
  2. Ge, E.J J., Bush, A.I., Casini, A.,  Cobine, P.A., Cross, J.R., DeNicola, G.M., Dou, Q.P., Franz, K.J., Vishal M. Gohil, V.M., Gupta, S., Stephen G. Kaler, S.G., Lutsenko, S., Mittal, V., Petris, M.J., Polishchuk, R., Ralle, M., Michael L. Schilsky, M.L., Tonks, N.K., Vahdat, L.T., Van Aelst, L., Xi, D., Yuan, P., Brady, D.C.# & Chang, C.J.# Connecting copper and cancer: from transition metal signalling to metalloplasia in the clinic. Nat Rev Cancer 22, 102-113 (2022).

​​​​​​​EDITORIALS & REVIEWS (* shared first authorship or # shared corresponding author)

  1. Brady, D.C.# & Weeraratna, A.T.# The Race toward Equity: Increasing Racial Diversity in Cancer Research and Cancer Care. Cancer Discov 10, 1451-1454 (2020).
  2. Brady, D.C. Cultivating a Safe Space: An Interview with Dr. Donita Brady. Mol Cell 80, 747-748 (2020).
  3. Tsang, T.*, Davis, C.I.*, & Brady, D.C. Copper biology. Curr Biol 31, R421-R427 (2021). 
  4. Brady, D.C.#, Hmeljak, J, & Dar, A.C.# Understanding and drugging RAS: 40 years to break the tip of the iceberg. Dis Model Mech15, dmm049519 (2022).
  5. Cobine, P.A.# & Brady, D.C.# Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death. Mol Cell 82, 1786-1787 (2022).
  6. Dar, & Brady, D.C.# RASopathy mutations open new insights into the mechanism of BRAF activation. Mol Cell 82, 4192-4193 (2022).